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Résumé en
anglais
Ciprofloxacin (CIP) is a poorly soluble drug that also displays poor permeability.
Attempts to improve the solubility of this drug to date have largely focused on the
formation of crystalline salts and metal complexes. The aim of this study was to
prepare amorphous solid dispersions (ASDs) by ball milling CIP with various
polymers. Following examination of their solid state characteristics and physical
stability, the solubility advantage of these ASDs was studied, and their permeability
was investigated via parallel artificial membrane permeability assay (PAMPA).
Finally, the minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) of the ASDs were compared to those of CIP. It was discovered
that acidic polymers, such as Eudragit L100, Eudragit L100-55, Carbopol, and
HPMCAS, were necessary for the amorphization of CIP. In each case, the positively
charged secondary amine of CIP was found to interact with carboxylate groups in the
polymers, forming amorphous polymeric drug salts. Although the ASDs began to
crystallize within days under accelerated stability conditions, they remained fully X-
ray amorphous following exposure to 90% RH at 25 °C, and demonstrated higher
than predicted glass transition temperatures. The solubility of CIP in water and
simulated intestinal fluid was also increased by all of the ASDs studied. Unlike a
number of other solubility enhancing formulations, the ASDs did not decrease the
permeability of the drug. Similarly, no decrease in antibiotic efficacy was observed,
and significant improvements in the MIC and MBC of CIP were obtained with ASDs
containing HPMCAS-LG and HPMCAS-MG. Therefore, ASDs may be a viable
alternative for formulating CIP with improved solubility, bioavailability, and
antimicrobial activity.
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